leadf
logo-loader
viewTodos Medical Ltd.

Todos Medical says new data from Tollovid study shows its ability to inhibit the 3CL protease, a key element of coronavirus replication

Inhibiting the 3CL protein could stop the ability of the coronavirus to replicate and prevent its spread throughout the body

Todos Medical Ltd. -
Researchers believe the 3CL protease plays a significant role in coronavirus replication

Todos Medical Ltd (OTCQB:TOMDF) has announced positive in vitro data for its dietary supplement Tollovid that shows its ability to inhibit the 3CL protease, an enzyme that facilitates intracellular replication of coronaviruses.

Tollovid is an orally administered proprietary blend of plant extracts that includes a powerful 3CL protease inhibitor that helps support and maintain healthy immune function.

Todos and its joint venture partner NLC Pharma said that researchers believe the 3CL protease plays a significant role in coronavirus replication, allowing the processing of proteins encoding viral RNA. Inhibiting this activity could stop the ability of the virus to replicate and prevent its spread throughout the body.

READ: Todos Medical reports positive initial proof-of-concept data for its rapid COVID-19 test

As part of NLC Pharma's development activities for Tollovid, a joint study was conducted at Tel Aviv University that examined the ability to impede the activity of enzyme 3CL. The study showed that Tollovid, which is an extract of a botanical substance, was able to successfully inhibit the 3CL protease activity.

In Israel, over 1,000 patients suffering from diseases caused by circulating coronaviruses have received various dosing regimens of Tollovid, including both hospitalized and non-hospitalized patients. In a statement, Todos said that there has been “overwhelmingly positive” customer feedback, including significant positive feedback from physicians.

Based on the results of this market research study conducted in Israel, as well as previous research in Israel, NLC Pharma is preparing to initiate a randomized clinical trial in Israel in December 2020 to evaluate the potential for Tollovid to treat patients suffering from actively circulating coronaviruses.

Todos is headquartered in Israel with offices in New York City.

Contact Angela at [email protected]

Follow her on Twitter @AHarmantas

Quick facts: Todos Medical Ltd.

Price: 0.055 USD

OTCQB:TOMDF
Market: OTCQB
Market Cap: $11.1 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Todos Medical Ltd. named herein, including the promotion by the Company of Todos Medical Ltd. in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Todos Medical reveals positive clinical proof of concept data from its rapid...

Todos Medical Ltd (OTCQB:TOMDF) CEO Gerald Commissiong tells Proactive the group has “positive clinical proof of concept data” from its lab-based rapid SARS-CoV-2 3CL protease diagnostic test in collaboration with its joint venture partner NLC Pharma. Commissiong says now, the group is...

1 week, 3 days ago

2 min read